GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)
GSK plc’s share price is pressing against 52‑week highs as 2025 draws to a close, with investors weighing a cluster of near‑term FDA decisions, a major CEO change on 1 January 2026, and a still‑busy share buyback programme. As of